Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024 Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting